AKT1 and neoplasm: Furthermore, preclinical studies in mice indicate that a daily dose of 25–30 mg/kg allows tumor regression and AKT inhibition in tumors, without leading to hyperglycemia and hyperinsulinemia (Fritsch et al, 2014).